MDS: Clinical Trials

7 trials for MDS, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated. 7 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Terminated 7
Phase 24Terminated 4

Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult
Phase 1 / Phase 2TerminatedBlueSphere Bio, Inc22025-02-042026-09-10
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
APR-548 + Azacitidine - MDS, Myelodysplastic Syndromes
Phase 1TerminatedAprea Therapeutics42021-09-202025-03-10
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
AMG 397, Dexamethasone, Azacitidine - Multiple Myeloma, Acute Myeloid Leukemia
Phase 1TerminatedAmgen242018-08-172023-04-12
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
E6201 - AML, MDS
Phase 1 / Phase 2TerminatedSpirita Oncology, LLC272015-04-102019-03-20
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
EPOCH-F/R, FLAG, Transplant Preparative Regimen (Flu/Cy/Mes) - Leukemia, Non-Hodgkins Lymphoma
Phase 1TerminatedNational Cancer Institute (NCI)42009-08-252019-12-17
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
Lenalidomide - Myelodysplastic Syndrome, MDS
Phase 1 / Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University82008-07-012025-05-04
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft
Naive T-cell Depleted Stem Cell Transplant, Stem Cell Transplant No Manipulation, Isolex device from Baxter - ALL, ANLL
Phase 1 / Phase 2TerminatedDuke University152007-07-012013-11-25

Narrower conditions

Leukemia, Myeloid, Acute (3)  ·  Myelodysplastic Syndromes (3)  ·  Lymphoma, Non-Hodgkin (2)  ·  Multiple Myeloma (2)  ·  Hodgkin Disease (1)  ·  Leukemia (1)  ·  Lymphoma (1)  ·  Recurrence (1)

Broader conditions

Hematologic Diseases (6)  ·  Hemic and Lymphatic Diseases (6)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Bone Marrow Diseases (3)  ·  Leukemia (3)  ·  Leukemia, Myeloid (3)  ·  Blood Protein Disorders (2)  ·  Cardiovascular Diseases (2)  ·  Hemorrhagic Disorders (2)  ·  Hemostatic Disorders (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)

Interventions

Azacitidine (2)  ·  14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione (1)  ·  Dexamethasone (1)  ·  Lenalidomide (1)  ·  Sirolimus (1)  ·  Tacrolimus (1)

Sponsors

Amgen (1)  ·  Aprea Therapeutics (1)  ·  BlueSphere Bio, Inc (1)  ·  Duke University (1)  ·  National Cancer Institute (NCI) (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)  ·  Spirita Oncology, LLC (1)

Countries

United States (6)  ·  Australia (1)  ·  France (1)  ·  Greece (1)  ·  Italy (1)  ·  Japan (1)

Top investigators

Emmanuel Besa, MD (1)  ·  Gautam Borthakur, MD (1)  ·  Joachim Gullbo, MD (1)  ·  Mitchell Horwitz, MD (1)  ·  Steven Z Pavletic, M.D. (1)